Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.3B
34M shares
52-week range
$45.85 – $79.29
66% from low
Sector
CHEMICALS & ALLIED PRODUCTS
Exchange
NYSE
CS
P/S (TTM)
2.1
EV / FCF (TTM)
22.9
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
www.ingevity.comNo one on the platform currently holds NGVT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 122,000 | $8.7M |
| Bridgewater Associatesas of 2026-03-31 | 17,366 | $1.2M |
No one on the platform has traded NGVT yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -17.0% | -0.8% | ||||
| Profit Margin % | -14.3% | -4.8% | 3.7% | |||
| Free Cash Flow Margin % | 23.4% | 11.3% | 12.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -1.0% on the P/E track.
At today's price, your expected annual return is +4.7% on the P/E track.
At today's price, your expected annual return is +9.6% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | -10.9% | $5.36 | $5.31–$5.42 | 12.7× | 2 |
| 2027 | $1.1B | +1.4% | $6.05 | $5.99–$6.11 | 11.2× | 2 |
| 2028 | $1.2B | +2.0% | $6.79 | $6.48–$7.11 | 10.0× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $1.33 | $1.74 | +30.8% |
| 2026-05-06 | $0.84 | $1.15 | +36.9% |
| 2026-02-25 | $0.67 | $0.58 | -12.8% |
| 2025-11-05 | $0.68 | $1.31 | +92.6% |
| 2025-08-04 | $1.02 | $1.39 | +36.3% |
| 2025-05-05 | $0.74 | $0.99 | +33.8% |
| 2025-02-18 | $0.29 | $0.95 | +227.6% |
| 2024-10-29 | $0.60 | $1.10 | +83.3% |
| $3.5B |
| — |
| FMCFMC Corporation | $11.43 | +4.05% | $1.4B | — |
| IOSPInnospec Inc. | $91.98 | +0.03% | $2.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 1.57 EPS for $NGVT Q3 [Reporting 11/04 AMC] http://www.estimize.com/intro/ngvt?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
$NGVT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.02 up 125.37% YoY • Reported revenue of $314.1M down -13.97% YoY • Ingevity Corporation raised its full-year 2026 outlook, expecting net sales of $1.05 billion to $1.15 billion, adjusted EBITDA of $380 million to $400 million, and diluted adjusted EPS of $5.00 to $5.45.
View on StockTwits ↗
$NGVT chop chop huckleberries and back up da Roger ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗
$NGVT Brilliant piece that captures NGVT's situation perfectly. So if you want to update your understanding of NGVT or get to know NGVT better, this is essential reading. https://everyticker.com/quote/NGVT/analysis/portfolio-surgery-meets-hybrid-tailwinds-at-ingevity-nyse-ngvt
View on StockTwits ↗
$NGVT Share Price: $71.26 Contract Selected: Oct 16, 2026 $77.5 Calls Buy Zone: $1.36 – $1.68 Target Zone: $2.31 – $2.82 Potential Upside: 60% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
https://marketbeat.com/a/8651338/ $NGVT Ingevity Q1 Earnings Call Highlights
View on StockTwits ↗
$NGVT Current Stock Price: $74.44 Contracts to trade: $75.0 NGVT May 15 2026 Call Entry: $3.60 Exit: $6.13 ROI: 70% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$NGVT Current Stock Price: $76.25 Contracts to trade: $75.0 NGVT May 15 2026 Call Entry: $0.50 Exit: $0.90 ROI: 81% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$NGVT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.70 up 203.57% YoY • Reported revenue of $258M down -9.15% YoY • Ingevity reaffirms full year 2026 guidance, expecting net sales between $1.05B and $1.15B, adjusted EBITDA between $370M and $395M, and adjusted EPS of $4.70 to $5.20.
View on StockTwits ↗
$NGVT just threw up a red flag ⚠️ Q4 swung to a loss, missing EPS estimates, with revenues down 3% year over year on weak auto demand and softer polymer sales. That’s not the kind of momentum you want heading into a new year. Is this a temporary dip or something deeper? See the full breakdown 👉 https://www.zacks.com/stock/news/2876186/ngvt-reports-losses-in-q4-missing-estimates-revenues-dip-yy?cid=sm-stocktwits-2-2876186-teaser-35381&ADID=SYND_STOCKTWITS_TWEET_2_2876186_TEASER_35381
View on StockTwits ↗$NGVT Q4 loss — is the growth story fading? 📉 Ingevity reported a loss of $2.37/share. Adjusted earnings missed Zacks Consensus by 16 cents, with revenue from continuing operations down 3% YoY. Advanced Polymer Tech sales slumped 17%, dragging segment EBITDA down 21% due to weak demand. Discover NGVT's 2026 outlook here 👉 https://www.zacks.com/stock/news/2876186/ngvt-reports-losses-in-q4-missing-estimates-revenues-dip-yy?cid=sm-stocktwits-2-2876186-body-35379&ADID=SYND_STOCKTWITS_TWEET_2_2876186_BODY_35379
View on StockTwits ↗$NGVT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$2.37 down -615.22% YoY • Reported revenue of $255.1M down -3.15% YoY • Ingevity expects full year 2026 net sales between $1.1B and $1.2B, adjusted EBITDA between $380M and $400M, and adjusted EPS between $4.80 to $5.20, with free cash flow of $225M to $250M.
View on StockTwits ↗$NGVT Current Stock Price: $75.29 Contracts to trade: $75.0 NGVT Feb 20 2026 Call Entry: $1.67 Exit: $2.97 ROI: 78% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗
$NGVT - Ingevity Options Alert: Put Open Interest Drops to 92.0 – Key Signal for Traders https://www.macroaxis.com/stock-options/NGVT/Ingevity-Corp?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.